CN Patent

CN100418970C — 伊立替康盐酸盐的同质多晶的制造方法

Assigned to Yakult Honsha Co Ltd · Expires 2008-09-17 · 18y expired

What this patent protects

提供水溶性好、杂质少的新的伊立替康盐酸盐同质多晶的制造方法。该方法是在粉末X射线衍射下在9.15°、10.00°、11.80°、12.20°、13.00°和13.40°具有衍射峰值(2θ)的伊立替康盐酸盐c型结晶的制造方法，该方法的特征在于，采用将伊立替康与选自丙酮、乙腈和四氢呋喃的一种或两种以上的溶剂混合，再加入盐酸而析出的结晶。

USPTO Abstract

提供水溶性好、杂质少的新的伊立替康盐酸盐同质多晶的制造方法。该方法是在粉末X射线衍射下在9.15°、10.00°、11.80°、12.20°、13.00°和13.40°具有衍射峰值(2θ)的伊立替康盐酸盐c型结晶的制造方法，该方法的特征在于，采用将伊立替康与选自丙酮、乙腈和四氢呋喃的一种或两种以上的溶剂混合，再加入盐酸而析出的结晶。

Drugs covered by this patent

ozanimod-hydrochloride (OZANIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: CN100418970C
Jurisdiction: CN
Classification: —
Expires: 2008-09-17
Drug substance claim: No
Drug product claim: No
Assignee: Yakult Honsha Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.